Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Faroux

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 24, 2009
Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled studyJean-Claude Barbare, Olivier Bouché, Franck Bonnetain, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2018
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trialsThomas Aparicio, Michel Ducreux, Roger Faroux, et al.
Hepatology International|January 9, 2021
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosisJean-Frédéric Blanc, Faiza Khemissa, Jean-Pierre Bronowicki, et al.
British Journal of Cancer|February 5, 2020
Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trialThomas Aparicio, Jaafar Bennouna, Karine Le Malicot, et al.
Bulletin Du Cancer|June 30, 2019
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]Marie-Anne Loriot, Fadil Masskouri, Paolo Carni, et al.
Seminars in Oncology|April 12, 2017
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approachMichele Boisdron-Celle, Olivier Capitain, Roger Faroux, et al.
Seminars in Oncology|September 20, 2017
In replyMichele Boisdron-Celle, Olivier Capitain, Roger Faroux, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2019
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trialPascal Hammel, Portales Fabienne, Laurent Mineur, et al.
Journal of Hepatology|May 25, 2019
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinomaJean-Louis Jouve, Thierry Lecomte, Olivier Bouché, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2020
Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial' [European Journal of Cancer, Volume 124 (January 2020) Pages 91-101]Pascal Hammel, Fabienne Portales, Laurent Mineur, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|March 24, 2009
Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled studyJean-Claude Barbare, Olivier Bouché, Franck Bonnetain, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2018
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trialsThomas Aparicio, Michel Ducreux, Roger Faroux, et al.
Hepatology International|January 9, 2021
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosisJean-Frédéric Blanc, Faiza Khemissa, Jean-Pierre Bronowicki, et al.
British Journal of Cancer|February 5, 2020
Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trialThomas Aparicio, Jaafar Bennouna, Karine Le Malicot, et al.
Bulletin Du Cancer|June 30, 2019
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]Marie-Anne Loriot, Fadil Masskouri, Paolo Carni, et al.
Seminars in Oncology|April 12, 2017
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approachMichele Boisdron-Celle, Olivier Capitain, Roger Faroux, et al.
Seminars in Oncology|September 20, 2017
In replyMichele Boisdron-Celle, Olivier Capitain, Roger Faroux, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2019
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trialPascal Hammel, Portales Fabienne, Laurent Mineur, et al.
Journal of Hepatology|May 25, 2019
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinomaJean-Louis Jouve, Thierry Lecomte, Olivier Bouché, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2020
Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial' [European Journal of Cancer, Volume 124 (January 2020) Pages 91-101]Pascal Hammel, Fabienne Portales, Laurent Mineur, et al.
Pageof 5